| Literature DB >> 18083562 |
Yvan Le Huerou1, Indrani Gunawardana, Allen A Thomas, Steven A Boyd, Jason de Meese, Walter Dewolf, Steven S Gonzales, May Han, Laura Hayter, Tomas Kaplan, Christine Lemieux, Patrice Lee, Jed Pheneger, Gregory Poch, Todd T Romoff, Francis Sullivan, Solly Weiler, S Kirk Wright, Jie Lin.
Abstract
Transketolase, a key enzyme in the pentose phosphate pathway, has been suggested as a target for inhibition in the treatment of cancer. Compound 5a ('N3'-pyridyl thiamine'; 3-(6-methyl-2-amino-pyridin-3-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium chloride hydrochloride), an analog of the transketolase cofactor thiamine, is a potent transketolase inhibitor but suffers from poor pharmacokinetics due to high clearance and C(max) linked toxicity. An efficient way of improving the pharmacokinetic profile of 5a is to prepare oxidized prodrugs which are slowly reduced in vivo yielding longer, sustained blood levels of the drug. The synthesis of such prodrugs and their evaluation in rodent models is reported.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18083562 DOI: 10.1016/j.bmcl.2007.11.100
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823